Karyopharm Therapeutics (KPTI) PT Raised to $22 at Baird; 'Expect a transformational year'

March 15, 2018 2:01 PM

Baird raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $22.00 (from $15.00) while maintaining a Outperform rating.Analyst Michael ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found